InsidersTradesSigma
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Discover the full record of transactions filed by O'Neill Gilmore Neil, Chief Executive Officer. Insider active across 1 company, notably Editas Medicine, Inc.. In total, 11 reports have been published. Split: 0 buy · 8 sells. Total volume traded: €225k. Activity tracked since 2 June 2022. The latest transaction was filed on 3 June 2026 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
11 of 11 declarations
Neil O'Neill is the Chief Executive Officer of Editas Medicine, Inc., a pioneering company in the field of genomic editing. Under his leadership, the company focuses on developing innovative therapies based on CRISPR technology. Neil brings extensive experience in biotechnology and business management, guiding Editas towards significant advancements in the treatment of genetic diseases.